AdaptHealth price target raised to $13 from $11 at Truist

Truist raised the firm’s price target on AdaptHealth (AHCO) to $13 from $11 and keeps a Buy rating on the shares. The company’s Q4 revenue and adjusted EBITDA were well ahead of estimates, driven by ongoing strength in Sleep/Respiratory, strong cost management and improvement in the Humana (HUM) contract implementation, the analyst tells investors in a research note.